FDA Approves Foundayo (Orforglipron): A Milestone in Oral GLP-1 Therapy for Obesity Management

On April 1, 2026, the U.S. Food and Drug Administration (FDA) announced the approval of Foundayo (orforglipron or LY3502970), a first-in-class non-peptide, orally administered glucagon-like peptide-1 receptor (GLP-1R) agonist. The approval marks a historic milestone as the first New Molecular Entity (NME) approved under the Commissioner’s National Priority Voucher (CNPV) pilot program, achieving the fastest approval of an NME since 2002.

Foundayo is indicated for use in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain long-term weight reduction in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition.

Current Landscape of GLP-1 agonists

A Glucagon-like peptide-1 receptor (GLP-1R) agonist is a type of medication that mimics the action of endogenous GLP-1, a naturally occurring hormone produced in the human gut in response to nutrient ingestion.² The most famous being the long-acting injectable peptides: Semaglutide (Wegovy or Ozempic) and Liraglutide (Saxenda).

Because GLP-1 is naturally degraded by enzymes in the body within minutes, these agonists are engineered to be more stable and long-acting, allowing them to exert their clinical effects for extended periods. GLP-1R agonists work through several distinct pathways to regulate metabolism and appetite, including:

1. Pancreatic α-Action (Incretin Effect)
   • Stimulates Insulin: When glucose levels rise, GLP-1R agonists (GLP1-RAs) signal the pancreatic β-cells to release insulin. Stimulating insulin secretion helps lower blood sugar levels.
   •  Inhibits Glucagon: Simultaneously, GLP1-RAs act on the α-cells to suppress the release of glucagon, a hormone that normally tells the liver to release more glucose into the bloodstream.³
   • Glucose-Dependence: Crucially, this action is "glucose-dependent," meaning the secretion of insulin only happens when blood sugar is high. This significantly lowers the risk of hypoglycemia (dangerously low blood sugar) compared to other diabetes medications.
2. CNS Activity (Appetite and Satiety)
   • Gut-Brain Axis: GLP-1RAs act on the brain (specifically the hypothalamus and the hindbrain) to modulate appetite.²
   • Satiety: enhance the feeling of fullness (satiety) and reduce hunger by modulating neurotransmitters like dopamine and glutamate
   • Reward Circuitry: They can dampen the "reward" sensation associated with palatable, high-calorie foods, which helps reduce cravings and binge eating.
3. Gastrointestinal Motility
   • Delayed Gastric Emptying: GLP-1RAs slow the rate at which food leaves the stomach. This prolongs the feeling of fullness after a meal, further reducing caloric intake and helping to stabilize post-meal glucose spikes.
4. Peripheral Effects
   • Inflammation: They exert anti-inflammatory effects by modulating cytokines and oxidative stress resulting in reduced adipose tissue inflammation. This translates to healthier adipose tissue with improved storage and fat releasing properties to ultimately help with weight loss.⁴
   • Renal and Cardiovascular Protection: Recent research suggests GLP-1RAs may protect the kidneys and heart by improving blood flow, reducing renal stress, and decreasing the risk of major adverse cardiovascular events.

The primary purpose of GLP-1R agonists is to manage metabolic diseases by addressing both the symptoms (high blood sugar, high weight) and the underlying drivers (insulin resistance, chronic inflammation).⁵

• Diabetes Management: To improve HbA1c (long-term blood sugar control) and reduce the risk of microvascular (kidney, retina) and macrovascular (heart attack, stroke) complications.
• Obesity and Weight Management: To promote sustainable weight loss through the combined effects of appetite suppression, increased satiety, and increased energy expenditure.
• Metabolic Disorders: To manage fat-related diseases like Non-Alcoholic Fatty Liver Disease (NAFLD) or Metabolic Dysfunction-Associated Steatohepatitis (MASH) by improving liver fat content.

A New Paradigm in Pharmacological Delivery

While the therapeutic landscape has been dominated by injectable peptide-based GLP-1 analogues (such as semaglutide and liraglutide), Foundayo represents a significant advancement in drug design. As a small molecule nonpeptide agonist, Foundayo offers the potential for higher bioavailability and superior patient compliance by removing the complexities associated with injectable administration.⁶

Mechanistically, orforglipron acts by binding to the GLP-1 receptor, activating the G protein-coupled signaling pathway to stimulate glucose-dependent insulin secretion, suppress glucagon release, and slow gastric emptying. 

Unlike injectable GLP-1 analogues which mimic the endogenous GLP-1 (1-36) peptide, orforglipron is a small molecule partial agonist a ligand that targets the GLP-1R. 

It is characterized by biased signaling, preferentially activating the G protein-coupled pathway (GPCR) over β-arrestin recruitment at the GLP-1R. This signaling profile is thought to produce favorable GLP-1 mimics a reduction in side effects.

Peptide-based drugs are also susceptible to rapid degradation by dipeptidyl peptidase-4 (DPP-4), orforglipron’s chemical stability allows for sustained activity and consistent efficacy. 

Overall, the drug has a pharmacokinetic advantage of sustaining high oral bioavailability and a favorable half-life, allowing for once-daily administration without the restrictive fasting requirements and low bioavailability of oral GLP-1 peptide drugs, for example, Rybelsus.

Foundayo Structure

The molecule's structure contains a hydrophobic aromatic indazole moiety for hydrophobic interactions at the left-side (Figure 1). An imidazolone linker conjugates indazole to the pyrazole-derived scaffold. Notably, a substituted pyrazole central core exists.⁶

Figure 1. Foundayo (orforglipron or LY3502970) structure

Structure-activity relationship studies indicate that orforglipron is a partial agonist with bias toward G-protein activation over β-arrestin recruitment. This bias is thought to result from the specific conformation it adopts in the binding site; the ligand induces a conformational change in the transmembrane region that is sufficient for G-protein coupling (leading to cAMP production) but insufficient to promote the recruitment of β-arrestin. This bias is thought to correlate with a favorable safety profile, potentially reducing the incidence of peptide-associated side effects like severe nausea and vomiting.

Researchers have further optimized Foundayo’s metabolic stability to survive through oral digestion by incorporating fluorine and methyl functional groups. The presence of fluorinated and methylated rings protects the molecule from proteolytic degradation and enhances intestinal absorption, allowing it to reach therapeutic concentrations in the systemic circulation after oral ingestion, a phenomenon that cannot be achieved with endogenous GLP-1 or most peptide analogs.

Clinical Efficacy: The ATTAIN Trials

The FDA decision was supported by the ATTAIN-1 and ATTAIN-2 Phase 3 clinical trial program. For example, in the ATTAIN-1 study:

• Weight Loss: Patients on the highest dose achieved an average weight loss of 27.3 pounds (12.4%) over 72 weeks, compared to 2.2 pounds (0.9%) in the placebo group.
• Metabolic Biomarkers: Significant decreases in non-HDL cholesterol, triglycerides, and systolic blood pressure were observed.

Safety and Tolerance Profile

The FDA noted that the safety profile of Foundayo is consistent with that of other GLP-1 receptor agonists.¹ The most frequently reported adverse reactions included gastrointestinal events such as nausea, vomiting, dyspepsia, diarrhea, and abdominal pain. 

The incidence of these symptoms tended to be highest during the initial dosage titration phase and significantly decreased as patients and healthcare providers stabilized on a maintenance dose.

As with other GLP-1 receptor agonists, Foundayo contains a boxed warning for thyroid C-cell tumors, which have been observed in rodent studies. It is contraindicated in patients with a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Recommended Dosage and Administration

Foundayo is administered as a once-daily oral tablet. A graduated dose escalation is used to minimize GI side effects:

Availability and Pricing

Lilly has and pledged to make Foundayo accessible through its LillyDirect program.⁷ The drug will be available at a launch price of $25 per month with commercial coverage and $149 for self-pay patients. This aggressive pricing strategy aims to lower the barrier to entry for this next-generation obesity treatment, making it an option for a broader demographic.

FDA Commissioner Martin Makary, M.D., M.P.H., stated: “This approval demonstrates what the FDA can achieve when we eliminate delays and prioritize fast and thorough work from the agency and industry partners. By cutting idle time and maintaining constant communications with the company throughout the review process, we completed this national priority review with outstanding efficiency, while upholding the FDA’s gold-standard science.”

David A. Ricks, Chair and CEO of Eli Lilly and Company, stated: “As a convenient, once-daily oral pill that delivers meaningful weight loss, Foundayo is obesity care designed for the real world. We believe it can help level the playing field for those living with obesity or who are overweight and living with weight-related complications.”

Outlook

Foundayo (orforglipron or LY3502170) is a potent, orally active, non-peptide small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist. Ongoing research suggests possible future applications in NASH, chronic kidney disease (CKD), and neurological disorders (e.g. Parkinson’s, Alzheimer’s).^2,10

---

References

1. FDA Approves First New Molecular Entity Under National Priority Voucher Program. U.S. Food and Drug Administration: FDA News Release, 2026.
2. Zheng, Z.; Zong, Y.; Ma, Y.; Tian, Y.; Pang, Y.; Zhang, C.; Gao, J. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy 2024, 9 (1), 234.
3. Kong, F.; Zhao, Y.; Zhang, W.; Wang, X.; Wu, T.; Zhou, Z.; Xu, Y.; Xia, L.; Sun, T. Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases. Nature Communications 2026, 17 (1), 972.
4.  Moiz, A.; Filion, K. B.; Tsoukas, M. A.; Yu, O. H. Y.; Peters, T. M.; Eisenberg, M. J. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. The American Journal of Medicine 2025, 138 (6), 934-940.
5. Moiz, A.; Filion, K. B.; Tsoukas, M. A.; Yu, O. H. Y.; Peters, T. M.; Eisenberg, M. J. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. eClinicalMedicine 2025, 86.
6. Kawai, T.; Sun, B.; Yoshino, H.; Feng, D.; Suzuki, Y.; Fukazawa, M.; Nagao, S.; Wainscott, D. B.; Showalter, A. D.; Droz, B. A.; et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proceedings of the National Academy of Sciences 2020, 117 (47), 29959-29967.
7. FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. Eli Lilly and Company: News Release, 2026.
8. Ma, X.; Liu, R.; Pratt, E. J.; Benson, C. T.; Bhattachar, S. N.; Sloop, K. W. Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Therapy 2024, 15 (4), 819-832.
9. Foundayo. Prescribing information. Eli Lilly and Company, 2026. Accessed July 28, 2026. www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf. 2026.
10. Melson, E.; Ashraf, U.; Papamargaritis, D.; Davies, M. J. What is the pipeline for future medications for obesity? International Journal of Obesity 2025, 49 (3), 433-451.